MCID: CLL004
MIFTS: 36

Cellular Myxoid Liposarcoma

Categories: Cancer diseases

Aliases & Classifications for Cellular Myxoid Liposarcoma

MalaCards integrated aliases for Cellular Myxoid Liposarcoma:

Name: Cellular Myxoid Liposarcoma 12 15
Round Cell Liposarcoma 12 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:5692
NCIt 51 C4252
SNOMED-CT 69 43296007
UMLS 74 C0334471

Summaries for Cellular Myxoid Liposarcoma

MalaCards based summary : Cellular Myxoid Liposarcoma, also known as round cell liposarcoma, is related to myxoid liposarcoma and mixed liposarcoma. An important gene associated with Cellular Myxoid Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Translational Control and Transcriptional misregulation in cancer. The drugs Trabectedin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Cellular Myxoid Liposarcoma

Diseases related to Cellular Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 32.4 CDK4 DDIT3 EWSR1 FUS HCCS MDM2
2 mixed liposarcoma 31.7 CDK4 DDIT3 FUS MDM2
3 liposarcoma 30.4 CDK4 DDIT3 EWSR1 FUS MDM2
4 myxofibrosarcoma 30.3 FUS MDM2
5 lipomatosis, multiple 29.9 CDK4 FUS MDM2
6 sarcoma 29.2 CDK4 DDIT3 EWSR1 FUS MDM2
7 fibrous histiocytoma 10.3 EWSR1 FUS
8 extraosseous chondrosarcoma 10.3 EWSR1 FUS
9 juxtacortical chondroma 10.3 EWSR1 FUS
10 sclerosing liposarcoma 10.3 FUS MDM2
11 extraskeletal ewing sarcoma 10.2 EWSR1 FUS
12 conventional central osteosarcoma 10.2 EWSR1 MDM2
13 ring chromosome 7 10.2 CDK4 MDM2
14 undifferentiated embryonal sarcoma of the liver 10.2 CDK4 MDM2
15 embryonal sarcoma 10.2 CDK4 MDM2
16 infiltrating angiolipoma 10.2 CDK4 MDM2
17 spindle cell lipoma 10.2 CDK4 MDM2
18 inflammatory mfh 10.2 CDK4 MDM2
19 soft tissue sarcoma 10.2 EWSR1 MDM2
20 lipoblastoma 10.2 CDK4 MDM2
21 malignant fibrous histiocytoma of bone 10.2 CDK4 MDM2
22 bone osteosarcoma 10.2 CDK4 MDM2
23 periosteal chondrosarcoma 10.2 CDK4 MDM2
24 periosteal osteogenic sarcoma 10.1 CDK4 MDM2
25 ischemic fasciitis 10.1 CDK4 MDM2
26 well-differentiated liposarcoma 10.1 CDK4 MDM2
27 ewing's family of tumors 10.1 CDK4 EWSR1
28 dedifferentiated liposarcoma 10.1 CDK4 MDM2
29 small cell sarcoma 10.1 CDK4 MDM2
30 clear cell sarcoma 10.1 EWSR1 FUS
31 infiltrating lipoma 10.1 CDK4 MDM2
32 muscle cancer 10.1 EWSR1 MDM2
33 juxtacortical osteosarcoma 10.1 CDK4 MDM2
34 peripheral osteosarcoma 10.1 CDK4 MDM2
35 malignant fibroxanthoma 10.1 CDK4 MDM2
36 fibrosarcoma of bone 10.1 CDK4 MDM2
37 histiocytoma 10.1 EWSR1 FUS MDM2
38 retinal cancer 10.0 CDK4 MDM2
39 atypical lipomatous tumor 10.0 CDK4 FUS MDM2
40 chondrosarcoma, extraskeletal myxoid 10.0 DDIT3 EWSR1 FUS
41 ocular cancer 10.0 CDK4 MDM2
42 malignant mesenchymoma 10.0 CDK4 EWSR1 MDM2
43 rhabdomyosarcoma 10.0 CDK4 EWSR1 MDM2
44 rhabdomyosarcoma 2 10.0 CDK4 EWSR1 MDM2
45 nervous system cancer 10.0 CDK4 EWSR1 MDM2
46 grade iii astrocytoma 10.0 CDK4 MDM2
47 sarcoma, synovial 9.9
48 pleomorphic lipoma 9.9
49 fibrosarcoma 9.9
50 spindle cell sarcoma 9.9

Graphical network of the top 20 diseases related to Cellular Myxoid Liposarcoma:



Diseases related to Cellular Myxoid Liposarcoma

Symptoms & Phenotypes for Cellular Myxoid Liposarcoma

GenomeRNAi Phenotypes related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

27 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.2 EWSR1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.2 CDK4 HCCS FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.2 CDK4 HCCS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.2 EWSR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.2 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.2 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.2 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.2 EWSR1 HCCS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.2 FUS
10 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.2 EWSR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.2 HCCS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.2 EWSR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.2 FUS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.2 CDK4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.2 HCCS FUS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.2 FUS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.2 FUS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.2 CDK4 EWSR1 HCCS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.2 CDK4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.2 EWSR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.2 HCCS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.2 HCCS FUS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.2 FUS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.2 FUS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.2 EWSR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.2 CDK4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.2 EWSR1
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.73 EWSR1
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.73 HCCS
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.73 EWSR1 HCCS
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.73 CDK4 EWSR1 HCCS
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.73 HCCS
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.73 CDK4 EWSR1
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.73 EWSR1
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.73 EWSR1

Drugs & Therapeutics for Cellular Myxoid Liposarcoma

Drugs for Cellular Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 3,Phase 1,Phase 2 114899-77-3 108150
2
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Epirubicin Approved Phase 3 56420-45-2 41867
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2
10 Alkylating Agents Phase 3,Phase 1,Phase 2
11 Immunologic Factors Phase 3,Phase 2,Phase 1
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2
14 Antibiotics, Antitubercular Phase 3,Phase 2
15 Anti-Bacterial Agents Phase 3,Phase 2
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Etoposide phosphate Phase 3
18 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimitotic Agents Phase 3
20
Isophosphamide mustard Phase 3,Phase 2 0
21 Antimetabolites, Antineoplastic Phase 3
22 Antimetabolites Phase 3
23 Antineoplastic Agents, Phytogenic Phase 3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
26
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
27
Mecasermin Approved, Investigational Phase 2 68562-41-4
28
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
29
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
30
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
31
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
32
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
33
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
34
Pembrolizumab Approved Phase 2 1374853-91-4
35
Mesna Approved, Investigational Phase 2 3375-50-6 598
36
Doxil Approved June 1999 Phase 2 31703
37
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
38
Efatutazone Investigational Phase 2 223132-37-4
39 HIV Protease Inhibitors Phase 2
40 Hormones Phase 2
41 Antineoplastic Agents, Hormonal Phase 2
42 Hormone Antagonists Phase 2
43 Antiemetics Phase 2
44 Anti-Inflammatory Agents Phase 2
45 Gastrointestinal Agents Phase 2
46 Autonomic Agents Phase 2
47 glucocorticoids Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
49 BB 1101 Phase 2
50
protease inhibitors Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
2 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
3 Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Unknown status NCT02275286 Phase 1, Phase 2 Trabectedin
4 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
5 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Completed NCT02609984 Phase 2
6 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Completed NCT01692496 Phase 2 Pazopanib
7 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
8 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
9 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
10 Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas Recruiting NCT02106312 Phase 2
11 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 2
12 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
13 Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Recruiting NCT03063632 Phase 2
14 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
15 Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial) Active, not recruiting NCT03816475 Phase 2
16 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Active, not recruiting NCT02249949 Phase 2 efatutazone
17 Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Suspended NCT03397186 Phase 2 Trabectedin
18 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
19 Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Completed NCT01477021 Phase 1 cyclophosphamide
20 NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Recruiting NCT03399448 Phase 1 Cyclophosphamide;Fludarabine
21 Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma Recruiting NCT03450122 Phase 1 Cyclophosphamide;Immunotherapeutic Combination Product CMB305
22 MAGE-A4ᶜ¹º³²T for Multi-Tumor Recruiting NCT03132922 Phase 1
23 Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Not yet recruiting NCT03670069 Phase 1 Itacitinib
24 NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Withdrawn NCT02059850 Phase 1 Cyclophosphamide
25 Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn NCT02210104 Phase 1 Ipilimumab;Cyclophosphamide
26 Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Active, not recruiting NCT01957709 Not Applicable

Search NIH Clinical Center for Cellular Myxoid Liposarcoma

Genetic Tests for Cellular Myxoid Liposarcoma

Anatomical Context for Cellular Myxoid Liposarcoma

MalaCards organs/tissues related to Cellular Myxoid Liposarcoma:

42
T Cells, Bone, Heart, Testis, Adipocyte, Liver

Publications for Cellular Myxoid Liposarcoma

Articles related to Cellular Myxoid Liposarcoma:

(show all 48)
# Title Authors Year
1
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. ( 29280411 )
2018
2
Hypercellular round cell liposarcoma: A comprehensive cytomorphologic study and review of 8 cases. ( 28469314 )
2017
3
Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma. ( 28903344 )
2017
4
Myxoid-round cell liposarcoma: MRI appearance after radiation therapy and relationship to response. ( 29484077 )
2017
5
Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. ( 27495042 )
2016
6
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. ( 26595521 )
2016
7
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. ( 24457462 )
2014
8
Cell senescence in myxoid/round cell liposarcoma. ( 25093008 )
2014
9
Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma. ( 25393000 )
2014
10
Paratesticular myxoid/round cell liposarcoma harboring type 3 DDIT3-FUS fusion gene: report of a very rare case. ( 23276404 )
2013
11
Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. ( 23401071 )
2013
12
Round cell liposarcoma metastatic to the heart. ( 23808478 )
2013
13
Round cell liposarcoma arising in the left foot: MRI and PET findings. ( 22965582 )
2012
14
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. ( 22020193 )
2012
15
Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. ( 22052112 )
2012
16
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. ( 22293175 )
2012
17
Myxoid/round cell liposarcoma of the supraclavicular fossa. ( 22359136 )
2012
18
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. ( 22359263 )
2012
19
Metastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experience. ( 22550416 )
2012
20
Subcutaneous myxoid and round cell liposarcoma. ( 21909204 )
2011
21
Round cell liposarcoma presenting as an FDG-positive primary with an FDG-negative retroperitoneal metastasis: a pitfall for F-18 FDG PET/CT imaging. ( 22064114 )
2011
22
Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. ( 22190864 )
2011
23
[Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. ( 19823827 )
2010
24
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. ( 18820664 )
2009
25
Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. ( 17653909 )
2007
26
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. ( 16651630 )
2006
27
Re: Oda et al. Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. J Pathol 2005;207:410-421. ( 16622896 )
2006
28
Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma. ( 16858687 )
2006
29
Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. ( 16177957 )
2005
30
Round cell liposarcoma of scrotum with indolent course in young adult. ( 16536120 )
2005
31
Cytomorphological features of combined myxoid and round cell liposarcoma--a case report. ( 16761768 )
2005
32
Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. ( 14975976 )
2004
33
Mixed myxoid/round cell liposarcoma of the scalp. ( 12649828 )
2003
34
Inconspicuous insertion 22;12 in myxoid/round cell liposarcoma accompanied by the secondary structural abnormality der(16)t(1;16). ( 12876210 )
2003
35
Primitive round cell liposarcoma of the omentum: diagnostic value of ultrastructural study. ( 14660282 )
2003
36
Cytologic features of round cell liposarcoma: a report on five patients. ( 12589643 )
2003
37
The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. ( 11213831 )
2001
38
Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. ( 11757867 )
2001
39
p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma. ( 10920137 )
2000
40
Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. ( 11229517 )
2000
41
Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption. ( 9268753 )
1997
42
Round cell liposarcoma with the insertion (12;16)(q13;p11.2p13). ( 9208976 )
1997
43
Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. ( 9403703 )
1997
44
Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. ( 8554106 )
1996
45
The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. ( 8608528 )
1996
46
Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma. ( 7485386 )
1995
47
Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. ( 7805034 )
1995
48
Primary round cell liposarcoma of the omentum. A case report. ( 1523931 )
1992

Variations for Cellular Myxoid Liposarcoma

Expression for Cellular Myxoid Liposarcoma

Search GEO for disease gene expression data for Cellular Myxoid Liposarcoma.

Pathways for Cellular Myxoid Liposarcoma

Pathways related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.42 DDIT3 EWSR1 FUS
2 11.19 DDIT3 EWSR1 FUS MDM2
3 11.11 CDK4 DDIT3
4 10.98 CDK4 MDM2
5 10.9 CDK4 MDM2
6 10.66 CDK4 MDM2

GO Terms for Cellular Myxoid Liposarcoma

Biological processes related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell cycle GO:0045787 8.96 CDK4 MDM2
2 negative regulation of cell cycle arrest GO:0071157 8.62 CDK4 MDM2

Molecular functions related to Cellular Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 8.62 CLEC18A CLEC18C

Sources for Cellular Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....